Literatur zum Titelthema “Pneumologie heute“
Bayerisches Ärzteblatt 11/2026, Seite 456 ff.
Autor: Professor Dr. Tobias J. Lange

Literatur

1. Lommatzsch M, Criée CP, de Jong CCM, Gappa M, Geßner C, Gerstlauer M, u. a. [Diagnosis and treatment of asthma: a guideline for respiratory specialists 2023 - published by the German Respiratory Society (DGP) e.V.]. Pneumologie. August 2023;77(8):461–543. doi:10.1055/a-2070-2135 PubMed PMID: 37406667.

2. Kyriakopoulos C, Gogali A, Markozannes G, Kostikas K. Biologic agents licensed for severe asthma: a systematic review and meta-analysis of randomised controlled trials. Eur Respir Rev Off J Eur Respir Soc. 30. April 2024;33(172):230238. doi:10.1183/16000617.0238-2023 PubMed PMID: 38657997; PubMed Central PMCID: PMC11040390.

3. Khaleva E, Rattu A, Brightling C, Bush A, Bourdin A, Bossios A, u. a. Definitions of non-response and response to biological therapy for severe asthma: a systematic review. ERJ Open Res. 2. Mai 2023;9(3):00444–2022. doi:10.1183/23120541.00444-2022 PubMed PMID: 37143849; PubMed Central PMCID: PMC10152254.

4. Valéry S, Habib-Maillard S, Roche N. Real-world super-response to biologics in severe asthma: A French monocentric retrospective cohort study. Respir Med Res. November 2023;84:101055. doi:10.1016/j.resmer.2023.101055 PubMed PMID: 37897876.

5. Basagaña M, Martínez-Rivera C, Padró C, Garcia-Olivé I, Martínez-Colls M, Navarro J, u. a. Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis. Ann Med. 56(1):2317356. doi:10.1080/07853890.2024.2317356 PubMed PMID: 38364218; PubMed Central PMCID: PMC10878334.

6. Rattu A, Dixey P, Charles D, Brightling C, Chung KF, Bossios A, u. a. Predictors of Response to Biologics for Severe Asthma: A Systematic Review and Meta-Analysis. Allergy. Januar 2026;81(1):24–55. doi:10.1111/all.70031 PubMed PMID: 40956008; PubMed Central PMCID: PMC12773690.

7. 2026 GOLD Report and Pocket Guide. Global Initiative for Chronic Obstructive Lung Disease - GOLD [Internet]. [zitiert 19. September 2026]. Verfügbar unter: https://goldcopd.org/2026-gold-report-and-pocket-guide/

8. Vogelmeier CF, Böhm M, Hurst JR, Kahnert K, Lange TJ, Taube C, u. a. From hospital to home: Practical guidance when caring for patients with COPD and heart disease. Eur J Intern Med. Mai 2026;147:106810. doi:10.1016/j.ejim.2026.106810 PubMed PMID: 41802970.

9. Fabbri LM, Celli BR, Agustí A, Criner GJ, Dransfield MT, Divo M, u. a. COPD and multimorbidity: recognising and addressing a syndemic occurrence. Lancet Respir Med. November 2023;11(11):1020–34. doi:10.1016/S2213-2600(23)00261-8 PubMed PMID: 37696283.

10. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, u. a. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 22. Mai 2003;348(21):2059–73. doi:10.1056/NEJMoa030287 PubMed PMID: 12759479.

11. Criner GJ, Sue R, Wright S, Dransfield M, Rivas-Perez H, Wiese T, u. a. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE). Am J Respir Crit Care Med. 1. November 2018;198(9):1151–64. doi:10.1164/rccm.201803-0590OC PubMed PMID: 29787288.

12. Tana A, Shah PL. Advanced bronchoscopy therapies for emphysema: current state and future potentials. Curr Opin Pulm Med. 1. März 2026;32(2):121–8. doi:10.1097/MCP.0000000000001236 PubMed PMID: 41606822.

13. Wahidi MM, Lentz RJ, Criner GJ, Gompelmann D, Ing AJ, Kapp CM, u. a. Bronchoscopic Lung Volume Reduction with Endobronchial Valves: A Consensus Statement on Practical Aspects of Patient Selection and Periprocedural Management. Respir Int Rev Thorac Dis. 2026;105(3):397–420. doi:10.1159/000548437 PubMed PMID: 40952939.

14. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, u. a. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. Januar 2023;61(1):2200879. doi:10.1183/13993003.00879-2022 PubMed PMID: 36028254.

15. Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, u. a. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 1. April 2021;384(13):1204–15. doi:10.1056/NEJMoa2024277 PubMed PMID: 33789009.

16. Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, u. a. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 20. April 2023;388(16):1478–90. doi:10.1056/NEJMoa2213558 PubMed PMID: 36877098.

17. Humbert M, McLaughlin VV, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, u. a. Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death. N Engl J Med. 29. Mai 2025;392(20):1987–2000. doi:10.1056/NEJMoa2415160 PubMed PMID: 40167274.

18. McLaughlin VV, Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, u. a. Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis. N Engl J Med. 23. Oktober 2025;393(16):1599–611. doi:10.1056/NEJMoa2508170 PubMed PMID: 41025556.

19. Souza R, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, u. a. Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial. Eur Respir J. September 2023;62(3):2301107. doi:10.1183/13993003.01107-2023 PubMed PMID: 37696565; PubMed Central PMCID: PMC10512088.

20. Preston IR, Badesch D, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, u. a. A long-term follow-up study of sotatercept for treatment of pulmonary arterial hypertension: interim results of SOTERIA. Eur Respir J. Juli 2025;66(1):2401435. doi:10.1183/13993003.01435-2024 PubMed PMID: 39978862; PubMed Central PMCID: PMC12287605.

21. Kovacs G, Zeder K, Humbert M, Condliffe R, Toews I, Boucly A, u. a. European Respiratory Society clinical practice guidelines update for the treatment of pulmonary arterial hypertension. Eur Respir J. 7. September 2026;2601178. doi:10.1183/13993003.01178-2026 PubMed PMID: 42705705.